Raw material prices softening; aim to double EBITDA in next 2-3 years: Rossari Biotech

Rossari Biotech has corrected 30 percent in last 3 months. Sunil Chari, Co-founder & MD of Rossari Biotech in an interview to CNBC-TV18 said, margins are likely to increase from Q2FY23 as prices for main raw materials have started declining.